These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 33430676)

  • 1. Drug survival of secukinumab, ustekinumab, and certolizumab pegol in psoriasis: a 2-year, monocentric, retrospective study.
    Chatzimichail G; Günther J; Ständer S; Thaçi D
    J Dermatolog Treat; 2022 May; 33(3):1749-1753. PubMed ID: 33430676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
    Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
    Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population.
    Xu C; Teeple A; Wu B; Fitzgerald T; Feldman SR
    J Dermatolog Treat; 2022 Jun; 33(4):2270-2277. PubMed ID: 34264149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Certolizumab Pegol Use in the Treatment of Moderate-to-Severe Psoriasis: Real-World Data From Two Canadian Centers.
    Vender RB; Lynde CW
    J Cutan Med Surg; 2022; 26(3):267-273. PubMed ID: 35134313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Certolizumab pegol in the treatment of psoriasis: Real-life data.
    Turkmen M; Dogan S
    Dermatol Ther; 2021 May; 34(3):e14929. PubMed ID: 33665940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis.
    Esposito M; Carubbi F; Giunta A; Alunno A; Giacomelli R; Fargnoli MC
    Expert Rev Clin Immunol; 2020 Feb; 16(2):119-128. PubMed ID: 31917928
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical efficacy and safety of certolizumab pegol in cutaneous symptoms on psoriasis in patients with psoriatic arthritis: A retrospective analysis in real life.
    Dattola A; Mazzeo M; Di Stefano F; Manfreda V; Vollono L; Di Raimondo C; Di Matteo E; Bianchi L
    Dermatol Ther; 2020 May; 33(3):e13409. PubMed ID: 32291887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison.
    Letarouilly JG; Flachaire B; Labadie C; Kyheng M; Cohen N; Sellam J; Richette P; Dieude P; Claudepierre P; Fautrel B; Houvenagel E; Nguyen CD; Guyot MH; Segaud N; Marguerie L; Deprez X; Salmon JH; Baudens G; Miceli-Richard C; Gervais E; Chary-Valckenaere I; Lafforgue P; Philippe P; Loeuille D; Richez C; Tubach F; Pham T; Flipo RM
    Rheumatology (Oxford); 2021 Jun; 60(6):2773-2782. PubMed ID: 33232465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
    Yiu ZZN; Mason KJ; Hampton PJ; Reynolds NJ; Smith CH; Lunt M; Griffiths CEM; Warren RB;
    Br J Dermatol; 2020 Aug; 183(2):294-302. PubMed ID: 32124442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of certolizumab pegol in a real-life cohort of patients with psoriasis and psoriatic arthritis.
    Carubbi F; Fidanza R; Palmieri M; Ventura A; Tambone S; Cipriani P; Giacomelli R; Fargnoli MC
    J Dermatolog Treat; 2020 Nov; 31(7):692-697. PubMed ID: 30963798
    [No Abstract]   [Full Text] [Related]  

  • 12. Certolizumab pegol for the treatment of psoriasis.
    Campanati A; Benfaremo D; Luchetti MM; Ganzetti G; Gabrielli A; Offidani A
    Expert Opin Biol Ther; 2017 Mar; 17(3):387-394. PubMed ID: 28165828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elderly psoriatic patients under biological therapies: an Italian experience.
    Ricceri F; Bardazzi F; Chiricozzi A; Dapavo P; Ferrara F; Mugheddu C; Romanelli M; Rongioletti F; Prignano F
    J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):143-146. PubMed ID: 29906311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies.
    Blauvelt A; Paul C; van de Kerkhof P; Warren RB; Gottlieb AB; Langley RG; Brock F; Arendt C; Boehnlein M; Lebwohl M; Reich K
    Br J Dermatol; 2021 Apr; 184(4):640-651. PubMed ID: 32531798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.
    Smolen JS; van Vollenhoven R; Kavanaugh A; Strand V; Vencovsky J; Schiff M; Landewé R; Haraoui B; Arendt C; Mountian I; Carter D; van der Heijde D
    Arthritis Res Ther; 2015 Sep; 17(1):245. PubMed ID: 26353833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study.
    Tanaka Y; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T
    Mod Rheumatol; 2014 Sep; 24(5):725-33. PubMed ID: 24372225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study.
    Tanaka Y; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T
    Mod Rheumatol; 2014 Sep; 24(5):734-43. PubMed ID: 24593170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial.
    Atsumi T; Tanaka Y; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Togo O; Okada T; van der Heijde D; Miyasaka N; Koike T
    Ann Rheum Dis; 2017 Aug; 76(8):1348-1356. PubMed ID: 28153828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial.
    Walsh JA; Gottlieb AB; Hoepken B; Nurminen T; Mease PJ
    Clin Rheumatol; 2018 Dec; 37(12):3285-3296. PubMed ID: 30191421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence and adherence of biologics in US patients with psoriatic arthritis: analyses from a claims database.
    Oelke KR; Chambenoit O; Majjhoo AQ; Gray S; Higgins K; Hur P
    J Comp Eff Res; 2019 Jun; 8(8):607-621. PubMed ID: 30912454
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.